Azilsartan: A newly approved angiotensin II receptor blocker

Cardiology in Review

Volumn 19, Issue 6, 2011, Pages 300-304

  Lam, Sum ^a,b  

^a ST JOHN'S UNIVERSITY   (United States)

^b WINTHROP UNIVERSITY HOSPITAL   (United States)

Author keywords

angiotensin II receptor blocker; azilsartan medoxomil; hypertension; renin angiotensin aldosterone system

Indexed keywords

AZILSARTAN MEDOXOMIL; CANDESARTAN HEXETIL; EPROSARTAN; IRBESARTAN; LOSARTAN POTASSIUM; OLMESARTAN; PLACEBO; TELMISARTAN; VALSARTAN;

ADJUVANT THERAPY; ANTIHYPERTENSIVE THERAPY; ARTICLE; ASTHENIA; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; COUGHING; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COST; DRUG ELIMINATION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; EDEMA; FATIGUE; HEADACHE; HUMAN; HYPERTENSION; HYPOTENSION; MUSCLE SPASM; NAUSEA; ORTHOSTATIC HYPOTENSION; PATIENT MONITORING; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; URINARY TRACT INFECTION;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANIMALS; BENZIMIDAZOLES; DRUG INTERACTIONS; HUMANS; HYPERTENSION; OXADIAZOLES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 80054041780     PISSN: 10615377     EISSN: 15384683     Source Type: Journal    
DOI: 10.1097/CRD.0b013e31822e9ba3     Document Type: Article

References (30)

1. Writing Groups, Lloyd-Jones D, Adams RJ, et al. Heart disease and stroke statistics-2010 update: A report from the American Heart Association. Circulation. 2010;121:e46-e215.
2. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. JAMA. 2003;289:2560-2572. (Pubitemid 37430158)
3. Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood pressure-lowering drugs. Lancet. 2000;356:1955-1964.
4. American Diabetes Association. Executive summary: Standards of medical care in diabetes-2011. Diabetes Care. 2011;34(suppl 1):S4-S10.
5. National Kidney Foundation. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease Am J Kidney Dis. 2004;43:11-13.
6. Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA. 2010;303:2043-2050.
7. Munger MA. Use of angiotensin receptor blockers in cardiovascular protection: Current evidence and future directions. P T. 2001;36:22-40.
8. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomized trial against atenolol. Lancet. 2002;359:995-1003. (Pubitemid 34286536)
9. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomized trial. Lancet. 2004;363:2022-2031. (Pubitemid 38781102)
10. Cohn JN, Tognoni G. A randomized trial of the angiotensin receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667-1675. (Pubitemid 33126822)
11. McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function taking angiotensin-converting enzyme inhibitors: The CHARM-Added trial. Lancet. 2003;362:767-771. (Pubitemid 37093916)
12. Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: The CHARM-Alternative trial. Lancet. 2003;362:772-776. (Pubitemid 37093917)
13. Brenner BM, Cooper ME, deZeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-869.
14. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-860.
15. Product Information: Edarbi oral tablets, azilsartan medoxomil oral tablets. Takeda Pharmaceuticals America, Inc., Deerfield, IL, 2011.
16. Saseen JJ, Maclaughlin EJ. Hypertension.In: Dipiro JT, Talbert RL, Yee GC, et al, eds. Dipiro's Pharmacotherapy: A Pathophysiologic Approach. 7th ed. New York, NY: McGraw-Hill; 2008:139-171.
17. White WB, Weber MA, Sica D, et al. Effects of the Angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. Hypertension. 2011;57:413-420.
18. Bakris GL, Sica D, Weber M, et al. The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure. J Clin Hypertens (Greenwich). 2011;13:81-88.
19. Drug price inquiry. Available at: Http://www.drugstore.com. Accessed May 27, 2011.
20. Sica D, Bakris GL, White WB, et al. New angiotensin II receptor blocker azilsartan medoxomil coadministered with chlorthalidone provides potent blood pressure reduction in stage 2 hypertension. Poster presented at: Annual Scientific Meeting, American Society of Hypertension; 2010; New York.
21. Azilsartan/chlorthalidone combo bests olmesartan/HCTZ in stage 2 systolic hypertension. Available at: Http://www.theheart.org/article/1230773.do. Accessed June 1, 2011.
22. Weber MA, White WB, Sica D, et al. Antihypertensive efficacy of the new angiotensin receptor blocker azilsartan medoxomil in combination with amlodipine. Poster presented at: Annual Scientific Meeting, American Society of Hypertension; 2010; New York.
23. Turnbull F, Neal B, Ninomiya T, et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: Meta-analysis of randomised trials. BMJ. 2008;336:1121-1123. (Pubitemid 351731743)
24. Staessen JA, Wang JG, Thijs L. Cardiovascular prevention and blood pressure reduction: A quantitative overview updated until 1 March 2003. J Hypertens. 2003;21:1055-1176.
25. Verma S, Mamdani M, Al-Omran M, et al. Angiotensin receptor blockers vs. angiotensin converting enzyme inhibitors and acute coronary syndrome outcomes in elderly patients: A population based cohort study (UMPIRE study results). J Am Soc Hypertens. 2007;1:286-294. (Pubitemid 47096558)
26. Turnbull F, Neal B, Pfeffer M, et al. Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. J Hypertens. 2007;25:951-958. (Pubitemid 46573113)
27. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomized trial-the Losartan Heart Failure Survival Study ELITE II. Lancet. 2000;355: 1582-1587. (Pubitemid 30240502)
28. Dickstein K, Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: The OPTIMAAL randomized trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet. 2002;360:752-760. (Pubitemid 35247704)
29. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349:1893-1906. (Pubitemid 37409706)
30. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547-1559. (Pubitemid 351522739)